Endocrine and metabolic risk factors for cardiometabolic disease

Olle Melander1,2,*

1Clinical Sciences, Malmö, Lund University, 2Department of Internal Medicine, Skåne Universioty Hospital, Malmö, Sweden

During the last years the knowledge of genetic determinants of cardiometabolic disease in general has exploded thanks to the success of genome wide association studies. Circulating biomarkers, especially cardiometabolic hormones and metabolites reflecting the genetic alterations, have been proven to sharpen up risk prediction of diabetes and cardiovascular disease on top of traditional risk factors. In addition, a number of examples of how these discoveries can be taken forward to highlight novel pathophysiological mechanisms, as well as drug and life-style modifiable targets of cardiometabolic disease, will be presented. In this context, there will be particular emphasis on the interface between diabetes and cardiovascular disease.  From a methodological point of view, a blend consisting of Mendelian Randomization studies and experimental interventions in both animals and humans is utilized. Recent data on three systems of potential importance in cardiometabolic disease will be shown; those being sortillin-1/neurotensin, vasopressin and specific metabolomics signatures along with preliminary data on how to potentially modify these systems by life style and drugs.

Keywords: Biomarker, Cardiovascular, Genomics